Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.1% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care Inc (TNDM) specializes in diabetes management solutions, specifically insulin pumps. Today, the company saw a significant decrease in its stock value.

Why is Tandem Diabetes Care, Inc. going down?

TNDM stock is down 5.1% on Jun 22, 2026 20:00

• The decline in TNDM's stock price may be due to the negative EPS forecast and revenue projections for the upcoming quarter, suggesting potential challenges for the company.
• Factors such as TNDM's financial risks and volatility, as noted in the risk assessment, could have raised concerns among investors, resulting in a sell-off.
• The absence of strong long-term support signals and the heightened downside risk highlighted in trading analysis could have intensified the bearish sentiment among investors.
• In summary, the bearish market movement in TNDM today is likely a result of poor earnings forecasts, high volatility, and perceived downside risks.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem Diabetes Care Inc (TNDM) Earnings Forecast: Future EPS & Revenue Growth Estimates

Tandem Diabetes Care Inc (TNDM) has an earnings forecast score of 7.33, ranking 142nd in its industry. Analysts have a consensus "Buy" rating with an average price target of $18.00 and an expected upside of 74.22%. The company's next quarter revenue is projected at $255.18 million, and EPS is expected to be -$0.33.

https://www.tradingkey.com/markets/stocks/nasdaq-tndm/earnings

Tandem Diabetes Care Inc (TNDM) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Tandem Diabetes Care Inc (TNDM), highlighting its volatility and financial risks. The company's risk assessment score is 5.08, placing it 86th out of 204 in its industry, with a beta of 1.59 indicating higher volatility compared to the S&P 500 index. The assessment covers maximum drawdown, return-to-drawdown ratios, and various volatility metrics over different timeframes.

https://www.tradingkey.com/markets/stocks/nasdaq-tndm/risk-assesment

Tandem Diabetes Care Inc (TNDM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Tandem Diabetes Care Inc (TNDM) by business segment and region. As of April 6, the company's revenue is primarily driven by its Pump segment, contributing 69.67%, with significant

https://www.tradingkey.com/markets/stocks/nasdaq-tndm/revenue

Precision Trading with Tandem Diabetes Care Inc. (TNDM) Risk Zones

This article provides a precision trading analysis for Tandem Diabetes Care Inc. (TNDM), highlighting neutral near and mid-term readings but a positive long-term bias. It outlines various trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and current risk parameters.

https://news.stocktradersdaily.com/news_release/34/Precision_Trading_with_Tandem_Diabetes_Care_Inc._TNDM_Risk_Zones_061826063802_1781779082.html

Precision Trading with Tandem Diabetes Care Inc. (TNDM) Risk Zones

This article by Stock Traders Daily provides a detailed analysis of Tandem Diabetes Care Inc. (TNDM) stock, highlighting neutral near and mid-term readings but a positive long-term bias. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss levels. The analysis also identifies elevated downside risk due to a lack of additional long-term support signals.

https://news.stocktradersdaily.com/news_release/1/Precision_Trading_with_Tandem_Diabetes_Care_Inc._TNDM_Risk_Zones_061826063802_1781779082.html

Trending Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.1% Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Down 5.2% Today

VeriSign Inc. ($VRSN) Stock Forecast: Down 5.3% Today

Robert Half Inc. ($RHI) Stock Forecast: Down 5.1% Today

ARM Holdings plc ($ARM) Stock Forecast: Down 5.8% Today

Super Micro Computer Inc ($SMCI) Stock Forecast: Up 7.4% Today

Groupon Inc. ($GRPN) Stock Forecast: Up 5.2% Today

QUALCOMM Incorporated ($QCOM) Stock Forecast: Up 5.4% Today

Netflix Inc. ($NFLX) Stock Forecast: Down 5.1% Today

Skyworks Solutions Inc. ($SWKS) Stock Forecast: Up 7.0% Today

Tandem Diabetes Care, Inc. Price History

04.05.2026 - TNDM Stock was up 8.9%

• Tandem Diabetes Care (TNDM) experienced a bullish movement today, likely driven by positive investor sentiment and growth prospects indicated by recent strategic business model transitions and international expansion efforts.
• The news of key executives, including the CEO and other officers, receiving significant RSU grants under the 2023 Long-Term Incentive Plan could have also contributed to the bullish momentum, signaling confidence in the company's future performance and aligning leadership interests with shareholder value.
• The reaffirmed 2026 guidance and strong solvency profile further reinforced investor confidence in Tandem's long-term prospects, despite near-term profitability challenges.
• Overall, the combination of growth initiatives, executive incentives, and financial stability likely fueled the bullish movement in TNDM stock today.

04.05.2026 - TNDM Stock was up 8.0%

• The positive sentiment surrounding Tandem Diabetes Care's (TNDM) leadership team receiving significant Restricted Stock Units (RSUs) under the 2023 Long-Term Incentive Plan could have contributed to the bullish movement in the stock market today. This act of granting equity awards may indicate confidence in the company's future performance.
• Granting RSUs to key executives, including the CEO, EVP, and CFO, helps align their interests with long-term shareholder value. This alignment might enhance investor confidence in TNDM's strategic direction and growth opportunities.
• Despite recent share price fluctuations and concerns over TNDM's valuation, the disclosure of equity awards to top management could potentially reassure investors about the company's dedication to driving sustainable growth and profitability, likely influencing the positive market movement.

16.05.2026 - TNDM Stock was up 5.1%

• Despite Tandem Diabetes Care's strong performance in Q1 earnings and revenue, leading to a 23.6% drop in stock value, there is speculation that market expectations did not align with the reported results.
• With a current undervaluation of 43.2% compared to the analyst price target of $29.20, investors may be driven by growth prospects, fueling the recent bullish movement.
• The 5.1% surge in TNDM shares could be linked to the company's promising growth potential, evident through a GF Score of 65/100, despite concerns surrounding financial strength and profitability.
• The positive momentum may also be influenced by advancements in the diabetes management sector, exemplified by Insulet's innovative "fully closed loop" automated insulin delivery system, which could pose a competitive edge for Tandem Diabetes Care.

18.05.2026 - TNDM Stock was down 5.8%

• The bearish movement in TNDM today could be attributed to the risk assessment highlighting higher volatility and financial risks, which might have made investors cautious.
• The notice to sell shares by insiders could have added selling pressure on the stock, signaling potential lack of confidence in the company's future performance.
• Despite the precision trading analysis indicating a positive long-term bias, the lack of dividend payouts and stock splits history might have deterred some investors looking for stable income or growth opportunities.
• Overall, the combination of risk factors, insider selling, and historical financial aspects could have contributed to the bearish sentiment surrounding TNDM today.

05.05.2026 - TNDM Stock was up 5.3%

• A recent insider trading activity involving the Chief Strategy Officer gifting shares to a family trust may have indicated confidence in the company's future outlook, contributing to favorable market sentiment.
• Tandem Diabetes Care's strategic shift in business model, efforts towards international expansion, and upcoming product launches are viewed as significant drivers for future revenue growth, appealing to investors.
• The recent allocation of Restricted Stock Units to the Chief Operating Officer may have also bolstered confidence in the leadership team's capabilities to propel the company's growth, further enhancing investor confidence.
• Despite concerns outlined in the valuation analysis, including competition and execution challenges, the overall positive developments and strategic initiatives by Tandem Diabetes Care appear to have outweighed these risks for investors, leading to the bullish market movement.

10.05.2026 - TNDM Stock was down 8.1%

• Notwithstanding Tandem Diabetes Care's recent milestones like obtaining CE mark approval in Europe for extended indications and introducing innovative products such as the Mobi Tubeless, the stock experienced a bearish trajectory today.
• The market's negative response may be attributed to concerns regarding competitive pressures and potential risks linked to global expansion.
• Some investors appear to be adopting a cautious stance on TNDM's capacity to achieve its ambitious revenue and earnings projections by 2029.
• Despite positive updates about the company, the prevailing sentiment towards Tandem Diabetes Care's stock appears to have been influenced by wider market conditions or particular investor perspectives, contributing to the downward movement in stock value.

12.05.2026 - TNDM Stock was up 5.8%

• Tandem Diabetes Care (TNDM) saw a notable increase in its stock price today driven by several positive factors:
• Encouraging results from studies on the company's fully closed loop automated insulin delivery system for Type 2 diabetes that eliminates carb-counting and insulin bolusing, leading to enhanced investor confidence.
• Obtaining CE Mark approval in Europe for expanded diabetes management indications, including pregnancy in Type 1 diabetes and adults with Type 2 diabetes, creating new market possibilities and strengthening Tandem's role in integrated diabetes care.
• Anticipation surrounding product innovations like the upcoming Mobi Tubeless launch and advancements in global expansion, promoting optimism about Tandem's future growth.
• Analysts' decision to maintain a Hold rating on Tandem Diabetes Care suggests a reserved outlook, potentially influenced by competitive market conditions despite positive company updates.
• Tandem's progress in technology, regulatory clearances, and market expansion strategies has spurred bullish activity in the stock price, indicating growing investor interest in the company's prospects within the diabetes management industry.

11.05.2026 - TNDM Stock was down 7.1%

• The company achieved CE Mark approval for expanded indications in Europe and made progress with product innovation. However, its stock trended bearishly.
• BofA Securities maintained a Hold rating and set a target price of $25, potentially impacting the lack of bullish momentum.
• Despite Tandem Diabetes Care's focus on international growth and new technological advancements, investors may be wary of competitive pressures within the diabetes management sector.
• The stock's recent positive performance and various news releases might have triggered profit-taking actions, influencing market response.

08.05.2026 - TNDM Stock was down 5.4%

• The bearish movement in TNDM stock could be attributed to a reaction by investors to recent CE mark approvals in the EU for expanded indications of its insulin pumps.
• Despite the news of expanded clearances for Tandem's insulin pumps, the market may have already priced in these developments, leading to profit-taking by traders.
• The initial market response to the expanded indications might have subsided as investors reevaluated the potential impact on Tandem's revenue and market share in the highly competitive diabetes management sector.

02.05.2026 - TNDM Stock was down 5.4%

• An upgrade of Tandem Diabetes Care to "Overweight" with an increased price target to $27 did not prevent the bearish movement, indicating other market factors at play.
• Historical challenges, such as a significant decline in stock price over the past year and low return on equity, likely contributed to the bearish trend.
• The filing of a shelf registration for an ESOP-related offering and changes in director removal rules may have raised concerns among investors.
• Despite the recent surge in stock price and positive sales data, the overall market sentiment towards Tandem Diabetes Care remains cautious, emphasizing the need for a thorough evaluation of the company's long-term prospects.

09.05.2026 - TNDM Stock was down 5.1%

• Despite recent progress in product advancements and market expansion, a bearish trend in TNDM stock today may be due to profit-taking by investors following a period of strong performance.
• The market's negative reaction could stem from concerns regarding TNDM's ability to sustain growth amidst rising competition in the diabetes management industry.
• Some investors may have anticipated more substantial announcements from Tandem Diabetes Care, leading to a minor letdown and subsequent selling pressure on the stock.

22.05.2026 - TNDM Stock was down 5.1%

• The decline in TNDM's stock price may be due to the negative EPS forecast and revenue projections for the upcoming quarter, suggesting potential challenges for the company.
• Factors such as TNDM's financial risks and volatility, as noted in the risk assessment, could have raised concerns among investors, resulting in a sell-off.
• The absence of strong long-term support signals and the heightened downside risk highlighted in trading analysis could have intensified the bearish sentiment among investors.
• In summary, the bearish market movement in TNDM today is likely a result of poor earnings forecasts, high volatility, and perceived downside risks.